Doxycycline Post-Exposure Prophylaxis (doxy-PEP) for the Prevention of Bacterial Sexually Transmitted Infections for Men Who Have Sex with Men and Transgender Women

References

1. 1.↵
   1. Bachmann LH,
   2. Barbee LA,
   3. Chan P,
   4. et al

   . CDC clinical guidelines on the use of doxycycline postexposure prophylaxis for bacterial sexually transmitted infection prevention, United States, 2024. MMWR Recomm Rep 2024;73:1–8.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Molina JM,
   2. Charreau I,
   3. Chidiac C

   , ANRS IPERGAY Study Groupet al. Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial. Lancet Infect Dis 2018;18:308–17.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Mayer KH,
   2. Traeger M,
   3. Marcus JL

   . Doxycycline postexposure prophylaxis and sexually transmitted infections. JAMA 2023;330:1381–2.

   OpenUrlPubMed
4. 4.↵
   1. Luetkemeyer AF,
   2. Donnell D,
   3. Dombrowski JC

   , DoxyPEP Study Teamet al. Postexposure doxycycline to prevent bacterial sexually transmitted infections. N Engl J Med 2023;388:1296–306.

   OpenUrlCrossRefPubMed